Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers

Eitemau Tebyg

• Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
  gan: Brealey, Noushin, et al.
  Cyhoeddwyd: (2015)
• Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
  gan: Day, Nicola C., et al.
  Cyhoeddwyd: (2020)
• InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions
  gan: Bourdin, Arnaud, et al.
  Cyhoeddwyd: (2021)
• Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
  gan: Chen, Xia, et al.
  Cyhoeddwyd: (2015)
• Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
  gan: Lal, Chitra, et al.
  Cyhoeddwyd: (2016)